The $14.3B non-vet services segment is the only corner of the $158B pet industry without a dominant national roll-up. Private equity has systematically consolidated dental, vet, and home services — non-vet pet services is several years behind that curve, which means first-mover buyers acquire at 2.77–3.32× SDE rather than 6–10× EBITDA.

The macro tailwind is structural, not cyclical. Thirty consecutive years of uninterrupted growth, including through two recessions, establishes this sector as acyclical. Millennial and Gen Z pet owners — who spend 2.4× more per pet than Boomers — are entering their peak earning years. Ownership rates hit record highs post-2020 and show no sign of reversing.

The playbook is clear: acquire one dog daycare or boarding facility at ~3× SDE in DFW or Austin, add mobile grooming routes as bolt-ons at 2–2.5× SDE, build a regional multi-location platform, and exit to a PE roll-up buyer at 5–8× EBITDA. The identical playbook produced 3–4× equity returns in vet care. The window to run it in non-vet services is open now — it will close.

The thesis is sound: 94% of operators are micro-sized, no dominant regional player exists in Germany or the UK, and EU heat pump mandates create a structural installation tailwind with locked-in maintenance contracts to follow. Entry at 3–5× EBITDA against a 10–12× platform exit is a legitimate 2–3× equity return if executed properly.

The critical filter is maintenance revenue mix. Operators deriving 60%+ of revenue from recurring service contracts trade at a meaningful premium at exit — and represent far lower revenue risk during ownership. Install-heavy operators look cheap for a reason: their revenue depends on government subsidy programmes that are politically volatile in both Germany and the UK.

The 52% LOI failure rate is a real friction, not a myth. Owner cold feet, certification transfer complications, and buyer financing gaps collectively kill more than half of deals before close. Execution discipline separates the buyers who get deals from those who spend 18 months on dead LOIs.

Rural Midwest 503A compounders are pricing at 3–4.5× EBITDA in direct outreach versus 6–8× on brokered listings. The gap exists because healthcare-focused PE has discovered independent pharmacy roll-ups but has not yet systematically worked the rural Midwest off-market. That information asymmetry is temporary.

The FDA's February 2026 Enforcement Campaign on GLP-1 essentially-a-copy compounding is the catalyst. Operators who pivot to peptide-led books — BPC-157, Ipamorelin, GHK-Cu — within 90 days of close will operate at 65–80% gross margins with no PBM intermediation and no shortage-resolution risk. Operators who don't will face enforcement through Q3 2026. The distinction between these two outcomes is a matter of months.

The thesis is not speculative: independent pharmacies grew +3.2% through 2008 and +11.8% through 2020 while equity markets collapsed. The cash-pay peptide model removes every vector of retail pharmacy margin compression. Acquire pre-pivot at 3–4× EBITDA, execute the peptide pivot within 90 days, and hold a fundamentally different asset class than what you bought.